Welcome to our dedicated page for Spectral AI SEC filings (Ticker: MDAIW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Spectral AI, Inc. filings document the reporting record for an emerging growth medical diagnostics company with common stock and Nasdaq-listed redeemable warrants. Current reports cover financial results, Regulation FD disclosures, BARDA funding for the DeepView® System, and executive employment or compensation arrangements.
Proxy materials describe annual meeting matters including director elections, auditor ratification, and share issuance authorization under a securities purchase agreement. The filings also identify warrant terms, common-stock voting matters, governance procedures, and capital-structure disclosures tied to the company’s wound-care diagnostic business.
Spectral AI, Inc. has appointed Darcy Bajko as Chief Commercial Officer, effective July 31, 2026. She will lead commercial activities, including the global launch of the FDA De Novo–cleared DeepView® System for burn indication.
Her compensation includes a $315,000 annual salary, an annual target bonus of up to 30% of base pay, and stock options to acquire 150,000 common shares vesting over three years, with full vesting upon a change of control.
Spectral AI, Inc. director John Michael DiMaio reported compensation-related equity awards in common stock and options. He received three grants of common stock totaling 44,000 shares on June 24–29, 2026 at prices ranging from $1.69 to $1.74 per share, bringing his direct common stock holdings to 2,731,847 shares.
He also holds equity incentives in derivative form: 100,000 underlying shares via restricted stock units with an exercise price of $1.84 per share expiring on April 20, 2036, 250,000 underlying shares via non-qualified stock options at $1.25 per share expiring on April 23, 2035, and two incentive stock option positions over 20,352 and 5,292 underlying shares at $1.67 per share expiring on May 15, 2034. Footnotes state that some options were fully vested on issuance, others were fully vested as of the filing date, and part of one grant vests upon achieving specified milestones, while the RSUs vest in two equal tranches on April 20, 2026 and April 1, 2027.
Spectral AI, Inc. reported the results of its 2026 Annual Meeting of Stockholders and highlighted a major regulatory milestone for its DeepView burn-assessment device. Stockholders holding 17,267,570 shares, or 54.3% of outstanding common stock, were represented. All five director nominees were re-elected for one-year terms, the appointment of Forvis Mazars LLP as independent auditor for 2026 was ratified, and the Hudson Bay Proposal authorizing the reservation and issuance of common shares under an October 24, 2025 Securities Purchase Agreement was approved.
The company also emphasized that its DeepView System for burn indication has received FDA De Novo clearance, enabling a transition toward commercial scaling. DeepView combines multispectral imaging and proprietary AI to predict burn-healing potential, processing image data in roughly 20–25 seconds based on a database of over 340 billion pixels, aiming to support faster and more accurate wound-care decisions.
Spectral AI, Inc. director John Michael DiMaio reported equity awards rather than market trades. He received 15,000 shares of Common Stock on May 29, 2026 at a reported value of $2.12 per share, and 2,500 shares on May 28, 2026 at $2.36 per share, both classified as grants or awards. Following these awards, his direct Common Stock holdings total 2,687,847 shares. The filing also lists existing derivative positions: 100,000 underlying shares from Restricted Stock Units at an exercise price of $1.84 expiring on April 20, 2036, a Non-Qualified Stock Option over 250,000 underlying shares at $1.25 expiring on April 23, 2035, and Incentive Stock Options over 20,352 and 5,292 underlying shares at $1.67 expiring on May 15, 2034. A footnote states that 50% of the RSUs vest on April 20, 2026 and 50% on April 1, 2027, highlighting a multi-year vesting schedule.
Spectral AI, Inc. director John Michael DiMaio received 32,233 shares of common stock as a grant or award at $2.61 per share, increasing his direct holdings to 2,670,347 shares. The filing also lists several equity awards that remain outstanding.
These include restricted stock units tied to 100,000 shares of common stock at a $1.84 exercise price, non-qualified stock options linked to 250,000 shares at $1.25, and incentive stock options covering 20,352 and 5,292 shares at $1.67. Footnotes state that some options are fully vested, others vest upon milestones, and the RSUs vest in two equal tranches in 2026 and 2027.
Spectral AI, Inc. announced that the U.S. Food and Drug Administration granted De Novo Classification for its DeepView® System for burn care. This clearance authorizes the company to begin commercial distribution of DeepView in the United States.
The DeepView System is a non-invasive predictive device that uses multispectral imaging and a proprietary AI algorithm to assess burn wounds’ healing potential, helping clinicians decide earlier which areas are unlikely to heal within 21 days and may need significant intervention. Image capture takes about 0.2 seconds, with AI processing completed in roughly 20–25 seconds.
The system has been trained and tested on a clinically validated database of over 340 billion pixels of burn wound image data. Development is supported in whole or in part by federal funding from BARDA under contract number 75A50123C00049, positioning Spectral AI to move from development into U.S. commercialization for burn indications.
Spectral AI, Inc. director Sadagopan Deepak reported a compensation-related equity award. On April 24, 2026, he received 25,000 shares of Common Stock at a price of $0.00 per share as a grant or award, bringing his directly held common shares to 25,000. He also holds fully vested stock options over additional common shares with exercise prices between $1.25 and $1.67 per share, and 25,000 restricted stock units tied to the company’s common stock.
Spectral AI, Inc. director Richard John Cotton reported stock-based compensation awards. He received grants of 8,818 shares of common stock at $2.40 per share and 5,882 shares at $2.33 per share, increasing his directly held common shares to 111,477.
The filing also lists existing equity awards, including non-qualified and incentive stock options and restricted stock units tied to common stock, with exercise prices between $1.25 and $1.84 per share and expirations between 2034 and 2036.
Spectral AI, Inc. director John Michael DiMaio reported new equity compensation and updated his holdings. On May 15, 2026, he received two grants of common stock totaling 25,000 and 1,887 shares at reporting prices of $2.16 and $2.12 per share. Following these awards, he directly owns 2,638,114 shares of common stock.
He also holds derivative awards, including Restricted Stock Units over 100,000 underlying shares at an exercise price of $1.84 expiring on April 20, 2036, Non-Qualified Stock Options over 250,000 shares at $1.25 expiring on April 23, 2035, and Incentive Stock Options over 20,352 and 5,292 shares at $1.67 expiring on May 15, 2034. Footnotes indicate various vesting schedules and milestone-based vesting for portions of these awards.
Spectral AI, Inc. ownership disclosure: Hudson Bay Capital Management and Sander Gerber report beneficial ownership of 1,671,416 shares, representing 4.99% of common stock on a defined basis. The reported figure assumes exercise of warrants held by Hudson Bay Master Fund Ltd., subject to a 4.99% Blocker.
The filing cites 31,823,895 shares outstanding as of March 23, 2006 for the percentage calculation and states that Mr. Gerber disclaims beneficial ownership while the Investment Manager may be deemed beneficial owner of the exercisable shares.